NEW YORK (GenomeWeb News) — Agilent Technologies and Groton Biosystems will co-market Groton’s Process Analytic Technology to pharmaceutical companies in North America, the companies said today.
PAT integrates Agilent’s 1200 series high-performance liquid chromatography instrument with Groton’s online sampling products and services. The tool is designed to help drug makers design, analyze, and control how raw and in-process materials are manufactured, the companies said.
As part of the deal the firms will market the tools at trade shows, customer events, and product presentations, the companies said.
The companies also said they expect in the “near future” to expand the agreement to Europe and Asia.
Financial terms of the agreement were not released.